lymphocytes

[EdiGene, Inc.] EdiGene, Inc. has entered into a research collaboration with the University of Wisconsin–Madison as part of the company’s effort of translating proprietary LEAPER™ RNA editing technology into in vivo therapies.

[Shoreline Biosciences] Dendreon Pharmaceuticals and Shoreline Biosciences, a biotechnology company developing allogeneic off-the-shelf, standardized, and targeted natural killer and macrophage cellular immunotherapies derived from iPSC for cancer, announced an alliance to advance the future of iPSC-derived cellular therapies.

[Cancer Gene Therapy] In the MC38 tumor model, combined administration of plasmids encoding IL-12 and an anti-PD-1 antibody induced significant anti-tumor responses, yet similar to the monotherapies.

[Journal of Translational Medicine] Researchers created a CAR-T that united in one product the two modalities: a CRISPR interference- circuit prevents programmed cell death protein 1 expression upon antigen-encounter.

[PLoS Neglected Tropical Diseases] Scientists investigated the expression of FOXP3+ Treg cells in leprosy skin lesions and to correlate their clinical forms, laboratory characteristics, and the immune reconstitution syndrome in HIV-leprosy co-infection.

[Journal of Neuroinflammation] There is increasing evidence that dendritic cells (DCs) are implicated as key modulators in keeping the balance between immune response and tolerance in the central nervous system.